316 related articles for article (PubMed ID: 16772343)
41. RET/PTC activation in hyalinizing trabecular tumors of the thyroid.
Papotti M; Volante M; Giuliano A; Fassina A; Fusco A; Bussolati G; Santoro M; Chiappetta G
Am J Surg Pathol; 2000 Dec; 24(12):1615-21. PubMed ID: 11117781
[TBL] [Abstract][Full Text] [Related]
42. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
43. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
44. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application.
Guerra A; Sapio MR; Marotta V; Campanile E; Moretti MI; Deandrea M; Motta M; Limone PP; Fenzi G; Rossi G; Vitale M
Endocr J; 2011; 58(1):31-8. PubMed ID: 21173509
[TBL] [Abstract][Full Text] [Related]
46. RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH.
Cinti R; Yin L; Ilc K; Berger N; Basolo F; Cuccato S; Giannini R; Torre G; Miccoli P; Amati P; Romeo G; Corvi R
Cytogenet Cell Genet; 2000; 88(1-2):56-61. PubMed ID: 10773666
[TBL] [Abstract][Full Text] [Related]
47. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia.
Chua EL; Wu WM; Tran KT; McCarthy SW; Lauer CS; Dubourdieu D; Packham N; O'Brien CJ; Turtle JR; Dong Q
J Clin Endocrinol Metab; 2000 Aug; 85(8):2733-9. PubMed ID: 10946873
[TBL] [Abstract][Full Text] [Related]
48. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells.
Gilbert-Sirieix M; Ripoche H; Malvy C; Massaad-Massade L
Thyroid; 2010 Oct; 20(10):1053-65. PubMed ID: 20615140
[TBL] [Abstract][Full Text] [Related]
49. RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas.
Learoyd DL; Messina M; Zedenius J; Guinea AI; Delbridge LW; Robinson BG
J Clin Endocrinol Metab; 1998 Oct; 83(10):3631-5. PubMed ID: 9768676
[TBL] [Abstract][Full Text] [Related]
50. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults.
Fenton CL; Lukes Y; Nicholson D; Dinauer CA; Francis GL; Tuttle RM
J Clin Endocrinol Metab; 2000 Mar; 85(3):1170-5. PubMed ID: 10720057
[TBL] [Abstract][Full Text] [Related]
51. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Soares P; Trovisco V; Rocha AS; Lima J; Castro P; Preto A; Máximo V; Botelho T; Seruca R; Sobrinho-Simões M
Oncogene; 2003 Jul; 22(29):4578-80. PubMed ID: 12881714
[TBL] [Abstract][Full Text] [Related]
52. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
53. RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.
Corvi R; Berger N; Balczon R; Romeo G
Oncogene; 2000 Aug; 19(37):4236-42. PubMed ID: 10980597
[TBL] [Abstract][Full Text] [Related]
54. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation.
Caudill CM; Zhu Z; Ciampi R; Stringer JR; Nikiforov YE
J Clin Endocrinol Metab; 2005 Apr; 90(4):2364-9. PubMed ID: 15671095
[TBL] [Abstract][Full Text] [Related]
55. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.
Dinets A; Hulchiy M; Sofiadis A; Ghaderi M; Höög A; Larsson C; Zedenius J
Eur J Endocrinol; 2012 Jun; 166(6):1049-60. PubMed ID: 22457234
[TBL] [Abstract][Full Text] [Related]
56. Oncogenic rearrangements of the ret proto-oncogene in thyroid tumors induced after exposure to ionizing radiation.
Bounacer A; Wicker R; Schlumberger M; Sarasin A; Suárez HG
Biochimie; 1997 Oct; 79(9-10):619-23. PubMed ID: 9466701
[TBL] [Abstract][Full Text] [Related]
57. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma.
Salvatore G; Giannini R; Faviana P; Caleo A; Migliaccio I; Fagin JA; Nikiforov YE; Troncone G; Palombini L; Basolo F; Santoro M
J Clin Endocrinol Metab; 2004 Oct; 89(10):5175-80. PubMed ID: 15472223
[TBL] [Abstract][Full Text] [Related]
58. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus.
Smida J; Salassidis K; Hieber L; Zitzelsberger H; Kellerer AM; Demidchik EP; Negele T; Spelsberg F; Lengfelder E; Werner M; Bauchinger M
Int J Cancer; 1999 Jan; 80(1):32-8. PubMed ID: 9935226
[TBL] [Abstract][Full Text] [Related]
59. BRAF mutations are uncommon in papillary thyroid cancer of young patients.
Penko K; Livezey J; Fenton C; Patel A; Nicholson D; Flora M; Oakley K; Tuttle RM; Francis G
Thyroid; 2005 Apr; 15(4):320-5. PubMed ID: 15876153
[TBL] [Abstract][Full Text] [Related]
60. RET oncogene expression of papillary thyroid carcinoma in Korea.
Chung KW; Chang MC; Noh DY; Oh SK; Choe KJ; Youn YK
Surg Today; 2004; 34(6):485-92. PubMed ID: 15170542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]